

Mark Cuban Buys \$50,000 In Carbon Offset Tokens, Puts Them On-Chain Every 10 Days



Samyuktha Sriram

November 16, 2021 • 1 min read



Billionaire investor **Mark Cuban** revealed that he has been increasingly involved in the process of tokenizing carbon offsets on the blockchain.

What Happened: In a [series of tweets](#), Cuban said he was been buying \$50,000 in carbon offsets every 10 days and then putting them on-chain as **Base Carbon Tonnes** (CRYPTO: BCT).

BCT are reference tokens that represent one tonne of carbon from the carbon credit issuer Verra's Verified Carbon Unit registry from 2008 or later.

The BCT tokens are bridged onto **Polygon** (CRYPTO: [MATIC](#)) by the Toucan Protocol. Meanwhile, decentralized autonomous organization KlimaDAO aims to drive BCT's price up and has accumulated over 9 million tonnes of carbon offsets worth \$100 million to date.

“KLIMA has been operational for less than 1 month. And it's a DAO. Which means it's direction is controlled by those who are in the community. So the opportunity is there for all of us to set the direction,” said Cuban.

“I'm still learning, with a long way to go, but I don't know why the platform couldn't apply the same approach to removal that it has to offsets,” he added.

KlimaDAO is in Cuban's [portfolio of investments](#), although the size of the investment remains undisclosed.

Photo by Gage Skidmore on Wikimedia Commons.

See more from Benzinga

- [Click here for options trades from Benzinga](#)
- [Ethereum Whale 'Gimli' Adds 31B Shiba Inu Tokens To M Holdings](#)

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

[Terms and Privacy Policy](#) [Privacy & Cookie Settings](#)

SIMPLYWALLST

Assessing CT Real Estate Investment Trust's Valuation After Recent Unit Price Gains

Simply Wall St

Sun, April 19, 2026 at 5:09 AM GMT+2 • 4 min read



Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide.

Assessing CT Real Estate Investment Trust after recent gains

CT Real Estate Investment Trust (TSX:CRT.UN) has caught investor attention after a recent price move, with the unit price at CA\$17.84 and returns of 9.9% over the past month and 5.7% over the past 3 months.

For readers tracking income focused real estate names in Canada, these returns sit alongside a market value of about CA\$4.25b and reported annual revenue of CA\$604.25 million, with net income of CA\$238.44 million.

[See our latest analysis for CT Real Estate Investment Trust.](#)

The recent 3.4% 7 day share price return and 9.9% 30 day share price return at CA\$17.84 sit within a broader pattern, with a 1 year total shareholder return of 28.1% that suggests momentum has been building rather than fading.

If CT Real Estate Investment Trust's move has you looking at other areas of the market, this can be a handy moment to broaden your search and uncover [2 top founder-led companies](#)

With units trading at CA\$17.84, just above the CA\$17.55 analyst price target but with an estimated 36% intrinsic discount, you have to ask: Is CT REIT still undervalued, or is the market already pricing in future growth?

Price to earnings of 17.8x: Is it justified?

On the numbers provided, CT REIT screens as undervalued on earnings, with a P/E of 17.8x compared with a DCF fair value estimate that sits well above the current CA\$17.84 unit price.

The P/E ratio compares the current unit price to earnings per unit and is a common way investors judge how much they are paying for each dollar of profit. For a REIT such as CT REIT, it gives a quick read on how the market is valuing its current earnings profile.

In this case, the P/E of 17.8x sits below both the North American Retail REITs industry average of 24.4x and a peer average of 34.7x. The SWS DCF model points to a future cash flow value of CA\$27.75 per unit, and the units are also described as trading 35.7% below an internal fair value estimate. Taken together, that combination of a lower-than-peer earnings multiple and a sizeable intrinsic discount indicates the market is pricing CT REIT's earnings more conservatively than many of its sector peers.

[See what the numbers say about this price — find out in our valuation breakdown.](#)

Result: Price-to-earnings of 17.8x (UNDERVALUED)

However, the heavy reliance on Canadian Tire as the key tenant, along with the current premium to the CA\$17.55 price target, could both challenge the bullish valuation case.

Story Continues

[Terms and Privacy Policy](#) [Privacy & Cookie Settings](#)

SIMPLYWALLST

Assessing Sarepta Therapeutics (SRPT) Valuation After Early siRNA Trial Results Spark Share Price Rebound

Simply Wall St

March 26, 2026 • 3 min read



SRPT ☆

[Find winning stocks](#) in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE.

Sarepta Therapeutics (SRPT) is back in focus after releasing early Phase 1/2 data for two investigational siRNA therapies, SRP-1001 and SRP-1003, targeting rare neuromuscular diseases with significant unmet medical need.

[See our latest analysis for Sarepta Therapeutics.](#)

The early siRNA data arrives after a sharp rebound in the shares, with a 1-day share price return of 34.98% and a 7-day share price return of 38.52% at a last close of \$23.77. However, the 1-year total shareholder return is a 67.38% decline, so recent momentum contrasts with weaker longer term results as investors reassess both pipeline potential and perceived risks.

If this kind of clinical news has your attention, it can be worth broadening your search to other rare disease and biotech names through our curated list of [36 healthcare AI stocks](#)

With the shares rebounding sharply yet still carrying a 1 year total return decline of 67.38%, and trading at a sizeable intrinsic discount, investors now have to ask: is this a reset opportunity, or is the market already pricing in future growth?

Most Popular Narrative: 15.3% Overvalued

At a last close of \$23.77 versus a fair value estimate of \$20.61, the most followed narrative sees Sarepta trading ahead of its modeled worth while still hinging heavily on Elevidys execution and broader gene therapy adoption.

The analysts have a consensus price target of \$20.61 for Sarepta Therapeutics based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of \$38.0, and the most bearish reporting a price target of just \$5.0.

[Read the complete narrative.](#)

Want to see what sits behind that wide range of outcomes? The narrative leans on a sharp profit swing, shifting margins and a richer future earnings multiple. The specific revenue path, profit timing and valuation bridge are where the story really gets interesting.

Result: **Fair Value of \$20.61 (OVERVALUED)**

[Have a read of the narrative in full and understand what's behind the forecasts.](#)

However, this depends on ELEVIDYS avoiding further safety or regulatory setbacks and on Sarepta managing high research spending that currently contributes to a loss of \$713.41 million.

[Find out about the key risks to this Sarepta Therapeutics narrative.](#)

Another Way To Look At Value

The analyst narrative currently frames Sarepta as 15.3% overvalued at \$23.77 versus a \$20.61 fair value. Yet our DCF model points in the opposite direction, indicating the shares are trading at a 69.8% discount to an estimated future cash flow value of \$78.79. Which interpretation seems more realistic to you?

Story Continues

[Terms and Privacy Policy](#) [Privacy & Cookie Settings](#)

PREMIUM

BTIG Initiates Madison Square Garden Entertainment at Buy

MT Newswires

April 7, 2026



MSGE ☆

Madison Square Garden Entertainment (MSGE) has an average rating of overweight and mean price target

PREMIUM

Upgrade to read this MT Newswires article and get so much more.

A Silver or Gold subscription plan is required to access premium news articles.

Upgrade

Already have a subscription? [Sign in](#)

[Terms and Privacy Policy](#) [Privacy & Cookie Settings](#)

A Look At Ryan Specialty Holdings (RYAN) Valuation After The Recent Share Price Slide

Simply Wall St

March 22, 2026 • 3 min read



 [StockStory Top Pick](#) 

RYAN +1.17% ☆

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St.

Ryan Specialty Holdings (RYAN) has drawn attention after recent share price weakness, with the stock showing negative returns over the past month and past 3 months. That slump is prompting fresh questions about valuation and fundamentals.

[See our latest analysis for Ryan Specialty Holdings.](#)

The recent slide extends beyond the last month, with a 90 day share price return showing a 33.32% decline and a 1 year total shareholder return showing a 50.73% decline, pointing to fading momentum as investors reassess growth potential and risk.

If this kind of reset has you reassessing your watchlist, it may be a good time to broaden your search using our screener of [20 top founder-led companies](#)

With Ryan Specialty Holdings now trading at US\$34.68, after a 33.32% 90 day slide and a 50.73% 1 year total shareholder return decline, is this reset creating a buying window, or is the market already discounting future growth?

Most Popular Narrative: 37.2% Undervalued

Ryan Specialty Holdings' most followed valuation narrative pegs fair value at \$55.25, well above the last close at \$34.68. This puts a spotlight on the growth and margin story underpinning that gap.

The company's continued expansion into higher-margin specialty lines, especially through product launches in alternative and complex risks and acquisition of niche MGUs, should increase the contribution from diverse, less commoditized business, stabilizing and growing earnings even when traditional property pricing cycles are volatile. Ryan Specialty's robust M&A

strategy, demonstrated by the successful integration of new businesses (e.g., USQRisk, 360° Underwriting, JM Wilson), is significantly growing its distribution network and client base. This inorganic growth lever is expected to support higher revenue and earnings.

[Read the complete narrative.](#)

Want to see what justifies a fair value well above the current share price? The narrative focuses on earnings, margins, and a potentially richer future profit multiple. Curious which revenue and margin assumptions really carry the model and how much execution room they leave? The full story lays out those moving parts in detail.

Result: Fair Value of \$55.25 (UNDERVALUED)

[Have a read of the narrative in full and understand what's behind the forecasts.](#)

However, those upside assumptions collide with real risks, including softer property pricing and M&A integration challenges that could pressure revenue, margins, and the whole earnings trajectory investors are modelling.

Story Continues

[Terms and Privacy Policy](#) [Privacy & Cookie Settings](#)

How Deep Yellow's Tumas Progress Is Shaping the Next Phase of Its Uranium Development Story

Habib Ur Rehman

March 24, 2026 • 2 min read



DYL.AX ☆

DYLLF ☆

Deep Yellow Limited (OTC:DYLLF) is one of the top nuclear energy stocks to buy in the next 5 years.

On March 6, 2026, Deep Yellow released its half-year financial report for the period ended December 31, 2025, outlining continued work across its Namibian and Australian uranium assets. The company reported a consolidated loss from continuing operations after tax of \$7.78 million, compared with \$2.47 million in the prior-year period, while total expenses rose to \$11.79 million from \$8.77 million. Cash and at-call deposits stood at \$187.15 million at

period-end, down from \$217.37 million at June 30, 2025. Capitalized mineral exploration and evaluation expenditure increased to \$334.83 million, and property, plant, and equipment rose to \$125.48 million, including \$119.30 million tied to the Tumas Project.



How Deep Yellow's Tumas Progress Is Shaping the Next Phase of Its Uranium Development Story

AlexKZ/Shutterstock.com

The company said Tumas remained its main development focus. By December 31, 2025, detailed engineering was more than 60% complete, bulk earthworks were about 24% complete, and more than 70% of major process plant equipment had been tendered. Deep Yellow also said an independent technical expert completed due diligence on Tumas in December and found no material issues. At Mulga Rock, the company continued work on a revised DFS, which is scheduled for completion in Q3 CY2026.

Deep Yellow Limited (OTC:DYLLF) is a uranium-focused exploration and development company with projects in Namibia and Australia, including the Tumas Project, Mulga Rock Project, and Alligator River Project.

While we acknowledge the potential of DYLLF as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the

onshoring trend, see our free report on the [best short-term AI stock](#). **READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.**
Disclosure: None. [Follow Insider Monkey on Google News.](#)

[Terms and Privacy Policy](#) [Privacy & Cookie Settings](#)

SIMPLYWALLST

Assessing Oversea-Chinese Banking's Valuation After Analyst Upgrade And Major Fund Inflows

Simply Wall St

April 13, 2026 • 3 min read



O39 ☆

O39.SI ☆

[Make better investment decisions](#) with Simply Wall St's easy, visual tools that give you a competitive edge.

Oversea-Chinese Banking (SGX:O39) is back in focus after an analyst upgrade tied to rising earnings estimates, as well as its key role in channeling S\$600 million of client inflows into the LionGlobal Singapore Trust Fund.

[See our latest analysis for Oversea-Chinese Banking.](#)

The recent analyst upgrade and OCBC's role in channeling S\$600 million of client inflows into the LionGlobal Singapore Trust Fund come against a backdrop of a 30 day share price return of 8.92% and a 1 year total shareholder return of 58.85%. This suggests that momentum has been building in how the market prices both its earnings profile and perceived risk.

If you want to see how other areas of the market are moving, now is a good time to widen your search and check out our [97 top founder-led companies](#)

With OCBC trading slightly above the average analyst price target yet showing a 34% intrinsic discount estimate, the key question is whether the recent strength is overdone, or if the market is still discounting future growth potential.

Most Popular Narrative: 8.2% Overvalued

OCBC's most followed narrative points to a fair value of S\$20.76, which sits below the current S\$22.47 share price and frames the latest upgrade in a different light.

The analysts have a consensus price target of SGD17.581 for Oversea-Chinese Banking based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of SGD20.15, and the most bearish reporting a price target of just SGD15.08.

[Read the complete narrative.](#)

Curious why the fair value sits above analyst targets yet below today's price? Revenue, margins and the future earnings multiple all pull this story in different directions.

Result: Fair Value of SGD20.76 (OVERVALUED)

[Have a read of the narrative in full and understand what's behind the forecasts.](#)

However, this narrative can still be knocked off course if interest rates cut into net interest margins or if wealth and insurance income remain volatile.

[Find out about the key risks to this Oversea-Chinese Banking narrative.](#)

Another View: Cash Flows Tell a Different Story

While the most popular narrative has OCBC trading about 8.2% above its S\$20.76 fair value, the SWS DCF model paints a different picture. On that view, the current S\$22.47 share price sits around 33.7% below an estimated cash flow value of S\$33.87. This points to a very different risk-reward balance for anyone focused on long-term cash generation.

Story Continues

[Terms and Privacy Policy](#) [Privacy & Cookie Settings](#)

SIMPLYWALLST

A Look At Madison Square Garden Sports (MSG) Valuation After Its New Impossible Foods Partnership

Simply Wall St

April 11, 2026 • 3 min read



IMPF.P... ☆

MSG ☆

[Never miss an important update on your stock portfolio](#) and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE.

Madison Square Garden Sports (MSG) has drawn fresh attention after announcing a multiyear partnership with Impossible Foods. The agreement introduces an Impossible Grille concession and expanded plant-based offerings at The Garden during Knicks and Rangers games.

[See our latest analysis for Madison Square Garden Sports.](#)

Investors appear to be responding positively to developments like the Impossible Foods partnership, with the share price at US\$331.07 and a 90 day share price return of 24.77%, while the 1 year total shareholder return sits at 73.86%.

If this kind of consumer brand partnership interests you, it could be a good moment to broaden your search and check out [18 top founder-led companies](#)

With MSG trading at US\$331.07, a 90 day return of 24.77% and a 1 year total shareholder return of 73.86%, investors may be asking whether there is still upside potential or if the market is already pricing in future growth.

Most Popular Narrative: 5% Undervalued

At a last close of \$331.07 versus an implied fair value of \$348.60, the most followed narrative sees modest upside grounded in media and fan engagement trends.

Persistent demand for live sports and premium arena experiences, as demonstrated by record-breaking gate receipts and suite revenues, combined with further investments in arena renovations and hospitality, is expected to drive stable or accelerating event-related revenue and higher average revenue per customer.

[Read the complete narrative.](#)

Want to understand why a single set of franchises supports this kind of valuation? The narrative leans heavily on steady revenue, firmer margins, and a richer future earnings multiple. The real story sits in how those assumptions fit together over time.

Result: Fair Value of \$348.60 (UNDERVALUED)

[Have a read of the narrative in full and understand what's behind the forecasts.](#)

However, this depends on media economics and costs cooperating, since reduced local rights fees and rising player and tax expenses could pressure margins and reset expectations.

[Find out about the key risks to this Madison Square Garden Sports narrative.](#)

Another Way To Look At The Valuation


The narrative points to a fair value of \$348.60, but the price tag looks very different when using sales as a yardstick. MSGS trades on a P/S of 7.4x, versus 1.3x for the US Entertainment industry, a 2.4x peer average and a fair ratio of 1x. That kind of gap can signal rich expectations, so how comfortable are you with what needs to go right to support it?

Story Continues


[Terms and Privacy Policy](#) [Privacy & Cookie Settings](#)

Recommended Stories







[Redacted article text]




[Redacted article text]



[Redacted article text]



[Redacted article text]



[Redacted article text]

yahoo!finance

Copyright © 2026 Yahoo.
All rights reserved.



Trending Topics

Dow Jones

S&P 500

DAX Index

Nvidia

Tesla

DJT

Tariffs

Explore Further

Mortgages

Credit Cards

[Sectors](#)

[Crypto Heatmap](#)

[Financial News](#)

About

[Data Disclaimer](#)

[Help](#)

[Feedback](#)

[Sitemap](#)

[Licensing](#)

[What's New](#)

[About Our Ads](#)

[Terms and Privacy Policy](#)

[Privacy & Cookie Settings](#)